Related Experiment Video
Updated: May 21, 2026

Cochlear Implant Surgery and Electrically-evoked Auditory Brainstem Response Recordings in C57BL/6 Mice
Published on: January 9, 2019
Gentamicin rapidly inhibits mitochondrial metabolism in high-frequency cochlear outer hair cells
Heather C Jensen-Smith1, Richard Hallworth, Michael G Nichols
1Department of Biomedical Sciences, Creighton University, Omaha, Nebraska, United States of America. heathersmith@creighton.edu
Abstract:
Aminoglycosides (AG), including gentamicin (GM), are the most frequently used antibiotics in the world and are proposed to cause irreversible cochlear damage and hearing loss (HL) in 1/4 of the patients receiving these life-saving drugs. Akin to the results of AG ototoxicity studies, high-frequency, basal turn outer hair cells (OHCs) preferentially succumb to multiple HL pathologies while inner hair cells (IHCs) are much more resilient. To determine if endogenous differences in IHC and OHC mitochondrial metabolism dictate differential sensitivities to AG-induced HL, IHC- and OHC-specific changes in mitochondrial reduced nicotinamide adenine dinucleotide (NADH) fluorescence during acute (1 h) GM treatment were compared. GM-mediated decreases in NADH fluorescence and succinate dehydrogenase activity were observed shortly after GM application. High-frequency basal turn OHCs were found to be metabolically biased to rapidly respond to alterations in their microenvironment including GM and elevated glucose exposures. These metabolic biases may predispose high-frequency OHCs to preferentially produce cell-damaging reactive oxygen species during traumatic challenge. Noise-induced and age-related HL pathologies share key characteristics with AG ototoxicity, including preferential OHC loss and reactive oxygen species production. Data from this report highlight the need to address the role of mitochondrial metabolism in regulating AG ototoxicity and the need to illuminate how fundamental differences in IHC and OHC metabolism may dictate differences in HC fate during multiple HL pathologies.
Insights
Gentamicin (GM) antibiotics damage hearing by harming cochlear outer hair cells (OHCs). Differences in OHC and inner hair cell (IHC) metabolism may explain why OHCs are more vulnerable to this hearing loss.
Area of Science:
- Ototoxicity
- Mitochondrial Metabolism
- Auditory Neuroscience
Background:
- Aminoglycosides (AG), like gentamicin, are widely used antibiotics.
- AG ototoxicity can cause irreversible hearing loss (HL) in a significant portion of patients.
- High-frequency outer hair cells (OHCs) are particularly vulnerable to HL, similar to AG ototoxicity.
Purpose of the Study:
- To investigate if differences in inner hair cell (IHC) and OHC mitochondrial metabolism influence their sensitivity to AG-induced HL.
- To compare IHC- and OHC-specific metabolic changes during gentamicin exposure.
Main Methods:
- Measured mitochondrial reduced nicotinamide adenine dinucleotide (NADH) fluorescence in IHCs and OHCs.
- Assessed succinate dehydrogenase activity.
- Compared metabolic responses to gentamicin and elevated glucose in high-frequency basal turn OHCs.
Main Results:
- Gentamicin caused rapid decreases in NADH fluorescence and succinate dehydrogenase activity.
- High-frequency basal turn OHCs showed metabolic biases, responding quickly to environmental changes like gentamicin and glucose.
- These metabolic biases may increase OHC susceptibility to reactive oxygen species (ROS) production during injury.
Conclusions:
- Mitochondrial metabolism plays a crucial role in regulating aminoglycoside ototoxicity.
- Fundamental metabolic differences between IHCs and OHCs likely dictate their differing fates in various HL pathologies.
- Understanding these metabolic differences is key to developing strategies against hearing loss.
Related Concept Videos
Inhibitors of Bacterial Protein Synthesis
The Electron Transport Chain
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
Hair Cells
The Cochlea
Antifungal Agents
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

